Health & Beauty Close-Up

CureVac Launches Construction on Industrial-Scale GMP Production Facility for RNA Therapeutics

CureVac reported the groundbreaking of its industrial-scale, GMP-compliant production facility at its headquarters in Tubingen, Germany.

According to a media release, the novel production facility called GMP IV will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expected to be fully commissioned in 2019.

"It fills me with pride and pleasure to see what was initially a visionary idea of RNA-based therapeutics now being manifested in such a huge production facility," said Dietmar Hopp, founder of SAP AG and investor in CureVac. "Together, we will continue doing everything so that this great vision becomes medical reality."

Ingmar Hoerr, Ph. …

Log in to your account to read this article – and millions more.